X

Trial Profile

Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific) Administered in Combination With Cemiplimab or REGN4018 (MUC16xCD3)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; REGN 5668 (Primary) ; Ubamatamab (Primary)
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Sponsors Regeneron Pharmaceuticals

Most Recent Events

15 Mar 2024 Planned number of patients changed from 326 to 612.
15 Mar 2024 Planned End Date changed from 19 Jul 2027 to 27 Apr 2027.
15 Mar 2024 Planned primary completion date changed from 18 Jan 2027 to 27 Apr 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com